

Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis

Maria A. Christou^{1,2} · Panagiota A. Christou¹ · Georgios Markozannes² · Agathocles Tsatsoulis¹ · George Mastorakos³ · Stelios Tigas¹ 

© Springer International Publishing Switzerland 2017

Abstract

Background Anabolic androgenic steroids (AAS) are testosterone derivatives used by athletes and recreational users to improve athletic performance and/or enhance appearance. Anabolic androgenic steroids use may have serious and potentially irreversible adverse effects on different organs and systems, including the reproductive system.

Objective This systematic review and meta-analysis aimed to critically assess the impact of AAS use on the reproductive system of athletes and recreational users.

Methods An electronic literature search was conducted using the databases MEDLINE, CENTRAL, and Google Scholar. Studies were included when the following criteria were fulfilled: participants were athletes or recreational users of any age, sex, level or type of sport; AAS use of any type, dose, form or duration; AAS effects on the reproductive system were assessed as stated by medical history, clinical examination, hormone and/or semen analysis. Random-effects meta-analysis was performed to assess the weighted mean difference (WMD) of serum gonadotropin

(luteinizing hormone, follicle-stimulating hormone) and testosterone levels compared with baseline, during the period of AAS use, as well as following AAS discontinuation.

Results Thirty-three studies (three randomized clinical trials, 11 cohort, 18 cross-sectional, and one non-randomized parallel clinical trial) were included in the systematic review (3879 participants; 1766 AAS users and 2113 non-AAS users). The majority of the participants were men; only six studies provided data for female athletes. A meta-analysis (11 studies) was conducted of studies evaluating serum gonadotropin and testosterone levels in male subjects: (1) prior to, and during AAS use (six studies, $n = 65$ AAS users; seven studies, $n = 59$, evaluating gonadotropin and testosterone levels respectively); (2) during AAS use and following AAS discontinuation (four studies, $n = 35$; six studies, $n = 39$, respectively); as well as (3) prior to AAS use and following AAS discontinuation (three studies, $n = 17$; five studies, $n = 27$, respectively). During AAS intake, significant reductions in luteinizing hormone [weighted mean difference (WMD) -3.37 IU/L, 95% confidence interval (CI) -5.05 to -1.70 , $p < 0.001$], follicle-stimulating hormone (WMD -1.73 IU/L, 95% CI -2.67 to -0.79 , $p < 0.001$), and endogenous testosterone levels (WMD -10.75 nmol/L, 95% CI -15.01 to -6.49 , $p < 0.001$) were reported. Following AAS discontinuation, serum gonadotropin levels gradually returned to baseline values within 13–24 weeks, whereas serum testosterone levels remained lower as compared with baseline (WMD -9.40 nmol/L, 95% CI -14.38 to -4.42 , $p < 0.001$). Serum testosterone levels remained reduced at 16 weeks following discontinuation of AAS. In addition, AAS abuse resulted in structural and functional sperm changes, a reduction in testicular volume, gynecomastia, as well as clitoromegaly, menstrual irregularities, and subfertility.

Electronic supplementary material The online version of this article (doi:10.1007/s40279-017-0709-z) contains supplementary material, which is available to authorized users.

✉ Stelios Tigas
stigas@cc.uoi.gr

¹ Department of Endocrinology, Medical School, University of Ioannina, Ioannina, Greece

² Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Ioannina, Greece

³ Endocrine Unit, 'Aretaieion' Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Conclusion The majority of AAS users demonstrated hypogonadism with persistently low gonadotropin and testosterone levels, lasting for several weeks to months after AAS withdrawal. Anabolic androgenic steroid use results in profound and prolonged effects on the reproductive system of athletes and recreational users and potentially on fertility.

Key Points

This is the first systematic review and meta-analysis of the effects of anabolic androgenic steroid use on the reproductive system of athletes and recreational users.

Anabolic androgenic steroid use results in a state of prolonged hypogonadotropic hypogonadism in male individuals; gonadotropin levels recover after 13–24 weeks, whereas serum testosterone does not appear to recover, remaining reduced at 16 weeks following discontinuation of anabolic androgenic steroids.

Anabolic androgenic steroid use is associated with changes in sperm characteristics, a reduction in testicular volume and gynecomastia in men, as well as clitoromegaly and menstrual irregularities in women and subfertility in both sexes.

1 Introduction

First identified in 1935, testosterone is the principal hormone controlling the development of androgenic-masculinizing effects in the male body, along with its anabolic properties that increase lean muscle mass [1]. The anabolic androgenic steroids (AAS) are testosterone derivatives used since the 1950s in an attempt to maximize the anabolic effects of testosterone, reduce the rate of its hepatic inactivation, and decrease its aromatization to estradiol [2]. Anabolic androgenic steroid formulations may be self-administered orally, parenterally by intramuscular injection, or transdermally in the form of a patch or topical gel.

Empirical evidence in the past suggested that AAS were mostly used by top-level competitive athletes and especially weightlifters, bodybuilders, and track athletes [3]. However, currently, AAS are widely used, not only by athletes involved in recreational and minor-league sports but also by non-athletes. Interestingly, at least four out of five AAS users are not competitive athletes but rather men who desire what they perceive to be an “enhanced” appearance [4].

It is estimated that 2.9–4.0% of Americans have used AAS at some time in their lives, while high rates of AAS

use have also been reported in many other regions of the world, such as Scandinavia, Brazil, British Commonwealth countries, and in continental Europe [5]. A meta-analysis indicated that the global lifetime prevalence rate of AAS use is 3.3%, with a higher rate of 6.4% in male individuals compared with 1.6% in female individuals [4]. In addition, AAS use appears more prevalent among teenagers compared with individuals aged older than 19 years; notably, 4–6% of high school boys have used AAS [4].

In the short term, AAS use results in few serious medical consequences, but their long-term use has been associated with several debilitating physical and psychological adverse effects and even increased mortality. Specifically, adverse effects may range from the development of acne or gynecomastia, to serious and life threatening effects such as an increased risk of cardiovascular disease and hepatic carcinoma [6, 7].

Normal gonadal function depends on the presence of intact hypothalamic pituitary gonadal axis activity through secretion of the gonadotropin-releasing hormone (GnRH) by the arcuate nucleus of the hypothalamus, as well as gonadotropins by the pituitary gland [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)]. Anabolic androgenic steroid use produces dose-dependent depression of gonadotropin release either by direct action on the pituitary gland or by suppression of the hypothalamic GnRH release. In male individuals, reduced gonadotropin secretion results in decreased intra-testicular and peripheral testosterone levels, leading to AAS-induced hypogonadotropic hypogonadism manifesting with testicular atrophy, oligospermia, azoospermia, and other sperm abnormalities [8]. Some male AAS abusers experience a lack of libido, erectile dysfunction, or even gynecomastia. Effects on the prostate gland include hyperplasia, hypertrophy, and possibly cancer [9]. In female individuals, the changes most often attributed to AAS abuse are menstrual irregularities (delayed menarche, oligomenorrhea, secondary amenorrhea), dysmenorrhea, anovulation, clitoral hypertrophy, libido changes, and uterine atrophy, with many of them being permanent [10]. Although some narrative reviews have been published in this area [9, 11–13], to our knowledge, this is the first systematic review and meta-analysis using explicit methodology to critically examine AAS effects on the reproductive system of both male and female athletes.

2 Methods

2.1 Protocol and Registration

The protocol of the study has been submitted to the PROSPERO international prospective register of systematic reviews (Registration Number: CRD42015017099) and the

guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement were followed [14].

2.2 Inclusion and Exclusion Criteria

Studies were included in the systematic review when the following criteria were fulfilled: participants were athletes or recreational users of any age, sex, level, or type of sport; AAS use of any type, dose, form, or duration; AAS effects on the reproductive system of athletes were assessed as stated by medical history, clinical examination, hormone analysis and/or semen analysis. Medical history and/or clinical examination referred to the assessment of specific signs and symptoms, such as testicular or clitoris size, regularity of menstruation, and changes in libido. At least one of the following three hormone values had to be reported: LH, FSH, and/or testosterone. Semen analysis included the measurement of different sperm characteristics, such as sperm concentration, motility, and morphology. No language, publication date, or publication status restrictions were imposed. All study designs were eligible except for case reports, case series, reviews, and meta-analyses. For studies on overlapping populations, the one providing the most complete data was included in the analysis. In the meta-analysis, studies were included when the mean hormone values and the standard deviation, or the necessary data to compute them, were provided for at least two time-points, i.e., at baseline, at the end of AAS use and/or at the end of the period of AAS discontinuation.

2.3 Study Selection and Data Extraction

Eligible studies were identified by searching electronic databases, scanning reference lists of included articles, and also after screening references of pertinent reviews. The search was applied to MEDLINE (PubMed), Cochrane Central Registry of Controlled Clinical Trials (CENTRAL), and Google Scholar (from inception to August 2016). The algorithm “(anabolic OR androgenic OR AAS) AND (reproduction OR fertility OR hormone OR semen OR sperm OR hypogonad*)” was used to search for all relevant studies in the aforementioned databases. Screening of the retrieved records (titles, abstracts, full texts) and data extraction of the included studies were performed independently in an unblinded standardized manner by two reviewers (M.A.C., P.A.C.). Disagreements between reviewers were resolved by consensus. If no agreement could be reached, then a third author (S.T.) decided.

2.4 Risk of Bias Assessment

Risk of bias of the included studies was assessed by the Cochrane Collaboration Tool for Randomized Controlled Trials [15]. The domains used pertain to randomization and allocation concealment (selection bias), blinding of

participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias. This tool assigns a judgment of high, unclear, or low risk of bias for each item. To draw conclusions about the overall risk of bias for each study, it is necessary to summarize assessments across the different domains. The RTI Item Bank tool, which consists of 13 questions, was used for the assessment of risk of bias in observational studies [16, 17]. Each study was given a score and graded as high, unclear, or low risk of bias based on the number of critical appraisal items met. The cut-off score was determined, based on previous systematic reviews and meta-analyses [18, 19] as follows; 0.00–0.30, high risk of bias; 0.31–0.70, unclear risk of bias; and 0.71–1.00, low risk of bias.

2.5 Statistical Analysis


Quantitative analysis was performed to assess the change from baseline in mean hormone values during the period of AAS use (i.e., prior to, and at the end of a period of active AAS use), as well as following AAS discontinuation (i.e., hormone levels at the end of a period of AAS discontinuation compared with those prior to AAS use and compared with those at the end of a period of AAS use). *P*-values lower than 0.05 were considered statistically significant. They were provided with precision at the third decimal point. All *p*-values lower than 0.001 were reported as <0.001. Random-effects meta-analysis was conducted owing to the presence of statistically significant heterogeneity in the included studies. The meta-analysis was based on the inverse variance method for weighting. The DerSimonian and Laird estimator was used to pool mean differences of each study and estimate the overall weighted mean difference (WMD), as well as 95% confidence interval (CI) [20]. Heterogeneity was assessed with the Cochran’s *Q* test statistic [21], with a *p*-value <0.1 denoting statistical significance. The degree of heterogeneity was assessed using the formula: $I^2 = 100\% * \frac{Q - (k-1)}{Q}$, where *k* represents the number of included studies [22]. The *I*² statistic ranges from 0% to 100% and cut-off values of 25, 50, and 75% indicate low, moderate, high, and very high degree of heterogeneity, respectively. Data analyses were conducted using the statistical program Stata (Version 13.1; StataCorp, College Station, TX, USA).

3 Results

3.1 Characteristics of Included Studies

Based on electronic databases search, 19,112 potentially eligible citations were identified. Thirty-four additional

Fig. 1 Preferred reporting items for systematic reviews and meta-analyses flow diagram



eligible studies were found through other sources. Of these 19,146 citations, 18,978 did not meet the inclusion criteria after reviewing the abstracts. The full text of the remaining 168 citations was examined in more detail. Thirty-five studies met the eligibility criteria. However, in four studies, overlapping populations were studied. Specifically, the study by Stromme et al. [3] referred to the same population as that of Aakvaag and Stromme [23], and therefore only the latter was included in the analysis as it provided more complete data. Studies by Holma and Adlercreutz and Holma included the same distinct population, but assessed different outcomes; they were therefore analyzed as a single study [24, 25]. Finally, 33 studies were included in the systematic review. The process of study selection is detailed in the flow diagram provided in Fig. 1.

One study [26] involved two partially overlapping populations for two separate experiments [methandienone experiment, $n = 12$ and dehydroepiandrosterone sulfate (DHEAS), experiment $n = 16$]. Owing to the fact that methandienone is considered a potent AAS, whereas DHEAS is actually a natural weak androgen and hormone precursor, results of the methandienone experiment were

included in the main analysis and the DHEAS experiment data were used for sensitivity analysis. Regarding study design, 11 cohort studies (33%), 18 cross-sectional studies (55%), three randomized controlled trials (9%), and one non-randomized parallel clinical trial (3%) were considered eligible. In the randomized controlled trials, either a parallel [23] or a cross-over design was used [26, 27].

The publication year of studies included in the analysis extended from 1972 to 2016, with most studies being published between 1980 and 1990 ($n = 10$, 30%). The majority of studies were conducted in Europe (18 studies, 55%; eight of which studies from Finland) and USA (11 studies, 33%). The median (25th–75th percentile) duration of the follow-up period was 24.5 (15–42) weeks. The language of all eligible publications was English.

3.1.1 Participants

The total number of participants in the studies included in the systematic review was 3879 (1766 AAS users and 2113 controls), with a mean (standard deviation) age of 28.7 (4.9) years. Most studies involved only men (27 out of 33

studies), four studies [28–31] referred only to women, and two more studies included both male and female athletes [32, 33]. The most common type of exercise was strength training and particularly bodybuilding, weightlifting, and powerlifting. When the comparator group was available, it usually referred to athletes not using AAS.

3.1.2 Type of Exposure/Intervention

Exposure or intervention in all eligible studies was AAS use. The median (25th–75th percentile) number of different AAS agents per study was 5.5 (3–11) and the median (25th–75th percentile) duration of AAS use was 12 (8–25) weeks. The AAS substances used more often were testosterone esters (94% of studies), methandrostenolone or methandienone (79% of studies), and stanozolol (67% of studies). The large diversity across different studies regarding the dose and route of AAS self-administration made the conduction of descriptive analysis for these parameters impractical. Characteristics of the included studies are shown in summary in Table 1 and in more detail in the Electronic Supplementary Material Table S1.

3.1.3 Outcome Definition and Method of Assessment

The main outcome was AAS effects on the reproductive system of athletes, as assessed by medical history and/or clinical examination (in 23/33 studies, 70%), hormone analysis (in 19/33 studies, 58%), and semen analysis (in 9/33 studies, 27%). The most common method of testosterone measurement was by radioimmunoassay (in 13/19 studies, 68%). Semen analyses were usually based on World Health Organization guidelines at the time (in 5/9 studies, 56%). In 14/33 studies (42%), athletes were followed for a period of time following AAS cessation, lasting 12–24 weeks (25th–75th percentile), with a median of 16 weeks.

3.2 Outcomes of Included Studies

Outcomes of the 33 eligible studies included the following: (1) changes of serum hormone levels (LH, FSH, testosterone) during AAS use, and following AAS discontinuation; (2) changes of semen characteristics during AAS use and following AAS cessation; and/or (3) reproductive system changes as assessed by medical history and/or clinical examination. To examine changes in endogenous testosterone during AAS use, we separately examined studies in which testosterone was included in the AAS regimen and studies in which the AAS used did not contain testosterone and/or the AAS compounds were such that interference with the levels of serum testosterone was unlikely (methandienone, mesterolone, nandrolone). The

outcome assessment is shown in Electronic Supplementary Material Tables S2 and S3.

3.2.1 Hormone Changes During AAS Use (Comparison of Hormone Levels Prior to, and During Active AAS Use)

Six studies, involving 65 AAS users, were included in LH and FSH meta-analysis [24, 26, 34–37]. The random-effects model suggested significant reductions in both LH (WMD -3.37 IU/L, 95% CI -5.05 to -1.70 , $p < 0.001$) and FSH levels (WMD -1.73 IU/L, 95% CI -2.67 to -0.79 , $p < 0.001$) during the period of AAS use (Fig. 2). There was significant high and moderate heterogeneity across these studies ($I^2 = 88.6\%$, $p < 0.001$ and $I^2 = 55\%$, $p = 0.049$, respectively). Five studies that did not fulfill the criteria for inclusion in the meta-analysis, showed that serum gonadotropin levels decreased from baseline when AAS use was started, or alternatively a lower level compared with controls or normal values was reported [27, 31, 38–41], whereas in three studies no difference was found [23, 42, 43].

Data analysis from studies in which testosterone had not been used in the AAS regimen [23, 24, 26, 34], comprising 43 AAS users, revealed a decrease in the endogenous blood testosterone level of 10.75 nmol/L (95% CI -15.01 to -6.49 , $p < 0.001$) during the period of AAS use (Fig. 2). High heterogeneity was found among studies ($I^2 = 87.8\%$, $p < 0.001$). Data analysis from studies in which testosterone was self-administered as part of the AAS regimen [35, 36, 44], involving 16 AAS users, revealed a marginally non-significant increase in testosterone levels (WMD 17.55 nmol/L, 95% CI -0.77 to 35.86, $p = 0.060$) (Fig. 2). There was significant high heterogeneity across studies ($I^2 = 75.9\%$, $p = 0.016$). The study by Bonetti et al. [37] was excluded from the analysis as testosterone was self-administered in some but not all study participants and testosterone levels were provided for the study population as a whole only (a non-significant decrease in testosterone of 1.15 nmol/L was reported). Another two studies that did not provide all necessary data to be included in the meta-analysis and in which testosterone was not part of the AAS regimen, reported a lower serum testosterone level during AAS use [27, 40], whereas, as expected, the opposite was reported in studies in which testosterone was included in the regimen [31, 38, 39, 42, 43]. Remarkably, in the study of Malarkey et al. [31], the mean serum testosterone levels were 30 times those found in the non-AAS female weightlifters or in the normal female population. In the study of Remes et al. [26], results for all three hormones did not differ, independent of whether the AAS agent used was DHEAS

Table 1 Studies characteristics

First author (year of publication)	N	Sex	Type of AAS	Duration of AAS use	Type of exercise	Duration of AAS cessation	Follow-up
<i>Cohort study</i>							
Al-Janabi (2011) [45]	24	Male	MD, ND, TE	NA	Bodybuilding	12 weeks	12 weeks
Garevik (2011) [41]	35	Male	TS, ND, ST	NA	Working out at gym facilities	12 months	12 months
Bonetti (2008) [37]	20	Male	NAN, NAL, NAND, NALD, AL, AN, DHEAS, MT, MD, OX, ML, NL, ST, TS	24 months	Bodybuilding	NA	24 months
Karila (2004) [39]	18	Male	MD, MS, OY, ST, MT, OX, FM, MAN, TU, TES, NL, ML, TR, BU, TS	NA	Power athletes	6 months ^a	6 months ^a
Alen (1987) [36]	15	Male	ST, NL, MD, TS	12 weeks	Power athletes	13 weeks	25 weeks
Martikainen (1986) [46]	6	Male	TS, MD, ND, ST	3 months	Power athletes	3 weeks	15 weeks
Alen (1985) [35]	11	Male	MD, ST, NL, TS	26 weeks	Bodybuilding, powerlifting, wrestling	16 weeks	42 weeks
Ruokonen (1985) [44]	9	Male	MD, NL, ST, TS	26 weeks	Power athletes	16 weeks	42 weeks
Alen (1984) [47]	14	Male	MD, NL, ST, ML, TS	6 months	Power athletes	6 months	12 months
Schurmeyer (1984) [34]	5	Male	NTH	13 weeks	Active in sports, undertake heavy physical training	Up to 24 weeks	Up to 37 weeks
Holma (1976) ^b [24]	16	Male	MD	2 months	Well-trained athletes	3 months	5 months
<i>Cross-sectional study</i>							
Börjesson (2016) [30]	8	Female	ST, ME, NL	NA	Bodybuilding, strength training, other sports	NA	NA
Kanayama (2015) [53]	55	Male	NR	NA	Weight lifting	NA	NA
Razavi (2014) [56]	250	Male	TS, NL, OY, O	NA	Bodybuilding	NA	NA
Coward (2013) [51]	80	Male	ND, ST, MD, TR, OX, OY, DP, BU, ME	NA	NR	NA	NA
Ip (2010) [32]	748	Males, female	OX, NL, BO, ST, MD, TP, TE	NA	Strength-trained exercise	NA	NA
Taher (2008) [40]	30	Male	MD, ML, OY, ND, TP, TB	NA	Bodybuilding	NA	NA
Perry (2005) [52]	207	Male	ND, TB, BO, ST, TR, TS, TC, TE, TP, MD, OX	NA	Bodybuilding, weight lifting, other sports	NA	NA
Urhaisen (2003) [38]	31	Male	DMT, FM, MS, ML, MD, OX, OY, ST, BO, DS, FB, NL, ETT	NA	Bodybuilding, powerlifting	NA	NA
Torres-Calleja (2001) [43]	30	Male	OY, MA, ND, TDP, MS, TE, TP	NA	Bodybuilding	NA	NA
Gruber (2000) [29]	75	Female	ST, MA, NL, OX, MS, BO, TES, MD, OY	NA	Bodybuilding, weight lifting	NA	NA
Evans (1997) [50]	100	Male	ND, ST, MD, ML, TR, OX, OY, DS, BO, TC, TP, TB, TH, TE, TU	NA	Weight training	NA	NA
Korkia (1997) [33]	1,669	Male, female	OX, ST, MD, TES, ND	NA	Subjects attending gymnasias	NA	NA
Pope (1994) [49]	156	Male	TS, NL, OY, ST, ML, BO, OX, MD, MS, MT, O	NA	Weight lifting	NA	NA

Table 1 continued

First author (year of publication)	N	Sex	Type of AAS	Duration of AAS use	Type of exercise	Duration of AAS cessation	Follow-up
Malarkey (1991) [31]	16	Female	MD, ST, ND, OX, TES, MI, MA, TRA, TR	NA	Weight lifting	NA	NA
Knuth (1989) [42]	82	Male	TES, NTE, MD, ML, ST, TR, BO, OX, CL, MS, OY	NA	Bodybuilding	NA	NA
Yesalis (1988) [55]	45	Male	MD, OX, OY, ST, ML, MS, FM, NE, MT, TES, NDE, TR, TA, BU, FB	NA	Powerlifting	NA	NA
Strauss (1985) [28]	10	Female	MS, MD, MA, MT, OX, ST, BU, ME, ND, SA, TC, MTE	NA	Weight training	NA	NA
Strauss (1983) [54]	39	Male	MD, OX, ST, ET, OY, MT, ND, TC, TE, ME, NP, TRB, TN, HM, THR	NA	Bodybuilding, powerlifting	NA	NA
<i>RCT</i>							
Remes (1977) ^c [26]	12	Male	MD	2 months	Runners	NA	8 months
Hervey (1976) [27]	11	Male	MD	12 weeks	Weight training	NA	20 weeks
Aakvaag (1974) [23]	21	Maales	MS	8 weeks	NR	NA	8 weeks
<i>Non-randomized parallel clinical trial</i>							
Johnson (1972) [48]	31	Male	MD	21 days	Weight training	NA	7 weeks


AAS anabolic androgenic steroids, *AL* androstenediol, *AN* androstenedione, *BO* boldenone, *BU* boldenone undecylenate, *CL* clostebol, *DHEAS* dehydroepiandrosterone sulfate, *DMT* 4-dehydrochloromethyltestosterone, *DP* drostanolone propionate, *DS* drostanolone, *ET* ethylestrenol, *ETT* different esters of testosterone and trenbolone, *FB* formebolone, *FM* fluoxymesterone, *HM* hexoxymestrolum, *MA* methenolone acetate, *MAN* methylandrostenedione, *MD* methandienone/methandrostenedione, *ME* methenolone enanthate, *MI* mibolerone, *ML* methenolone, *MS* mesterolone, *MT* methyltestosterone, *MTE* mixture of testosterone esters, *N* total number of participants, *NA* not applicable, *NAL* norandrostenediol, *NALD* 19-nor-4-androstenediol, *NAN* norandrostenedione, *NAND* 19-nor-4-androstenedione, *ND* nandrolone decanoate, *NDE* nandrolone esters, *NE* norethandrolone, *NL* nandrolone, *NP* nandrolone phenpropionate, *NR* not reported, *NTE* 19-nortestosterone esters, *NTH* 19-nortestosterone-hexoxyphenyl propionate, *O* other, *OX* oxandrolone, *OY* oxymetholone, *RCT* randomized controlled trial, *SA* stenbolone acetate, *ST* stanozolol, *TA* testosterone aqueous, *TB* testosterone blend, *TC* testosterone cyptonate, *TDP* testosterone decanoate and propionate, *TE* testosterone enanthate, *TES* testosterone esters, *TH* testosterone heptylate, *THR* therobolin, *TN* testosterone nicotinate, *TP* testosterone propionate, *TR* trenbolone, *TRA* trenbolone acetate, *TRB* trophobolone, *TS* testosterone, *TU* testosterone undecanoate

^a Duration of AAS cessation and follow-up are 6 months for hormone and semen analysis, and 6 years for fertility assessment (number of children conceived and successful pregnancies)

^b Data of the studies Holma and Adlerreutz [24] and Holma [25] were combined because they referred to overlapping populations and they assessed different outcomes

^c Data refer to characteristics of the methandienone experiment

Fig. 2 Hormone changes during anabolic androgenic steroid (AAS) use. *FSH* follicle-stimulating hormone, *LH* luteinizing hormone



or methandienone (sensitivity analysis, Electronic Supplementary Material Fig. S1).

3.2.2 Hormone Changes Following AAS Cessation (Comparison of Hormone Levels at the End of a Period of Active AAS Use and After a Period of AAS Discontinuation)

Four studies, involving 35 AAS users, were included in the LH and FSH meta-analysis [34–36, 39]. LH and FSH levels increased during the period following AAS withdrawal (WMD 2.68 IU/L, 95% CI 1.59–3.77, $p < 0.001$ and WMD 1.89 IU/L, 95% CI 1.05–2.74, $p < 0.001$, respectively) (Fig. 3). There was moderate heterogeneity across studies ($I^2 = 70.3%$, $p = 0.009$ and $I^2 = 54.5%$, $p = 0.066$, respectively). Consistent with these results, the two studies that were excluded from the meta-analysis because of a lack of appropriate data, showed that gonadotropin levels gradually recovered when AAS were withdrawn [41, 45].

Data analysis from studies in which testosterone was part of the AAS regimen [34–36, 39, 44], involving 34 AAS users, revealed, as expected, a decrease of testosterone levels following AAS cessation (WMD -28.04 nmol/L, 95% CI -45.11 to -10.98 , $p = 0.001$) (Fig. 3). High heterogeneity across studies was found ($I^2 = 75.5%$, $p = 0.003$). In the study of Schurmeyer et al. [34], in which testosterone was not included in the AAS regimen, a statistically significant increase in testosterone of 10.64 nmol/L was reported.

Finally, in a study that did not fulfill the criteria for inclusion in the meta-analysis and in which a control group was compared with a group of athletes during AAS use including testosterone, serum testosterone levels were lower compared with controls and did not increase significantly compared with the timepoint when AAS were withdrawn [45].

3.2.3 Hormone Changes Prior to AAS Use and After a Period of AAS Discontinuation

Three studies [34–36], including 17 AAS users, were included in LH and FSH meta-analysis. LH and FSH levels were similar to baseline at the end of a period (range 13–24 weeks) of AAS discontinuation (WMD 0.57 IU/L, 95% CI -0.60 to 1.74, $p = 0.340$ and WMD 0.43 IU/L, 95% CI -0.63 to 1.49, $p = 0.426$, respectively) (Fig. 4). There was non-significant low heterogeneity across studies ($I^2 = 0%$, $p = 0.524$ and $I^2 = 0%$, $p = 0.639$, respectively).

Data from four studies in which testosterone was self-administered as part of the AAS regimen [35, 36, 44, 46], involving 22 AAS users, revealed that serum testosterone levels at the end of a period of AAS discontinuation were

lower compared with baseline levels (WMD -9.40 nmol/L, 95% CI -14.38 to -4.42 , $p < 0.001$) (Fig. 4). The period of AAS discontinuation in these four studies ranged from 13 to 16 weeks apart from that in the study by Martikainen et al. [46], in which a shorter AAS discontinuation period of only 3 weeks was used, potentially explaining the larger serum testosterone level difference at the end of this study. There was non-significant moderate heterogeneity across studies ($I^2 = 36.6%$, $p = 0.192$). In the study of Schurmeyer et al. [34], in which testosterone was not included in the AAS regimen, endogenous serum testosterone levels returned to normal after 6 months.

3.2.4 Semen Changes During and Following AAS Use

Seven out of eight studies showed impairment of numerous sperm characteristics, such as total number, concentration, motility, and normal morphology [25, 34, 37, 39, 42, 43, 47]. However, in one study, no significant change in spermatogenesis was observed [48]. All studies in which this outcome was assessed showed persistent quantitative and qualitative sperm changes 8–30 weeks following AAS withdrawal [25, 34, 39, 42, 45, 47].

In general, in the above studies, changes were assessed and reported in a non-quantitative fashion. In the study by Holma [25], the ‘fertility index’ was used (a score based on sperm numbers, motility, quality of motility, and morphology). This index deteriorated during AAS use from 1.7 (3.0) to 14.7 (14.6), which is interpreted as ‘severely pathological’ [mean (standard deviation)] [25].

3.2.5 Outcomes Assessed by Medical History and/or Clinical Examination

A number of studies reported testicular atrophy [32–34, 37, 47, 49–52] in male athletes. Following AAS withdrawal, one study found that former AAS users displayed smaller testicular volumes compared with non-users [53]. However, testicular atrophy was more prominent among current than past users, indicating that testicular size tends to normalize after AAS withdrawal [49], although this may take up to 16 weeks [34]. Some studies reported gynecomastia in male individuals [32, 33, 37, 38, 50, 52, 54, 55], whereas two other studies stated no effects of AAS use regarding this outcome [34, 42]. Remarkably, in the study of Pope et al. [49], gynecomastia was equally common between current and past users, indicating that AAS-induced gynecomastia is often irreversible. In the only six studies involving female athletes, clitoromegaly and menstrual irregularities were reported as the main AAS-related side effect during the period of AAS use [28–33].

Only three studies determined AAS effects on fertility. In the study of Karila et al. [39], subjects were asked about

Fig. 3 Hormone changes following anabolic androgenic steroid (AAS) cessation. *FSH* follicle-stimulating hormone, *LH* luteinizing hormone









Fig. 4 Hormone changes during the overall period. *FSH* follicle-stimulating hormone, *LH* luteinizing hormone



the number of children conceived and successful pregnancies, and 6 years following AAS cessation, 55.56% (10/18) of them reported having at least one child, whereas the same outcome during the period of AAS use was 27.78% (5/18). Additionally, Coward et al. [51] mentioned that 11.3% (9/80) of the subjects stated infertility/low sperm count during the period of AAS use in a self-reported questionnaire. Similarly, in the study of Korkia et al. [33], 6% of the male athletes and 7% of the female athletes reported having fertility problems.

3.3 Risk of Bias Assessment

Based on the Cochrane Collaboration Tool for Randomized Controlled Trials, all studies [23, 26, 27] were rated as of unclear risk. Regarding randomization, allocation concealment, and selective reporting, the total risk of bias was unclear. Concerning blinding of participants and personnel, blinding of outcome assessment, and incomplete outcome data, the overall risk of bias was low.

Based on the RTI Item Bank tool, nine cohort studies (82%) were rated as having an unclear risk of bias [24, 35–37, 41, 44–47], one study (9%) as having a high risk [39] and one more study (9%) as having a low risk of bias [34]. Moreover, of low risk were the following items: sample definition and selection (Question 1), soundness of information (Question 6), follow-up (Question 7), and interpretation of results (Question 11). All the other questions were rated as of high or unclear risk of bias. Seven cross-sectional studies (39%) were of unclear risk of bias [29, 31, 38, 40, 42, 43, 49], ten studies (55%) were rated as high risk [28, 30, 32, 33, 50–52, 54–56], and one more study (6%) was of low risk [53]. Furthermore, the creation of treatment group (Question 3) and interpretation of results were rated as low risk (Question 11). All the other questions were rated as having a high or unclear risk of bias. The results for the assessment of risk of bias are shown in the Electronic Supplementary Material Table S4.

4 Discussion

4.1 Main Findings

To our knowledge, this is the first comprehensive systematic review and meta-analysis examining the effects of AAS use on the reproductive system of athletes and recreational users. As few studies focused on female subjects, the meta-analysis involved exclusively studies on male athletes and recreational users. Anabolic androgenic steroids use results in a state of prolonged hypogonadotropic hypogonadism in male individuals; gonadotropin levels recover 13–24 weeks after discontinuation of

AAS, whereas serum testosterone remains reduced at 16 weeks. Moreover, a systematic review of available evidence revealed that long-term AAS use results in prolonged hypogonadotropic hypogonadism in both sexes, changes in sperm characteristics, a reduction in testicular volume and gynecomastia in men, as well as clitoromegaly and menstrual irregularities in female individuals.

In almost all studies included in the meta-analysis, there were reductions in serum LH and FSH levels during the period of active AAS use (Fig. 2). Specifically, AAS suppress gonadotropin release from the pituitary through negative feedback mechanisms, either directly on the pituitary gland or indirectly through suppression of the hypothalamic GnRH release. The lack of a clear effect on gonadotropin levels in some studies may be explained by the low dosage and/or short period of AAS use, or by the self-administration of synthetic AAS with weak androgenicity compared with testosterone [23, 42, 43].

In addition, during AAS use, the meta-analysis revealed a reduction in basal serum testosterone levels (Fig. 2). In addition to causing a drop in levels of endogenous testosterone by inhibiting gonadotropin secretion, AAS use might also accelerate the metabolic clearance rate of testosterone or inhibit its biosynthesis by direct action on the gonads [24]. As expected, in studies in which exogenous testosterone was included in the AAS regimen, plasma levels of testosterone were considerably increased during AAS use (Fig. 2).

In two studies, gonadal function was assessed by the human chorionic gonadotropin (hCG) or LH-releasing hormone stimulation test. Notably, in subjects that had been using high AAS doses for a period of 3 months, the testicular responsiveness to a single injection of hCG was similar to that in prepubertal boys [46]. Moreover, Holma and Adlercreutz [24] showed that in well-trained athletes who had been taking 15 mg of methandienone daily for 8 weeks, post-stimulation testosterone values after LH-releasing hormone administration were lower compared with those prior to AAS use. HCG has also been used as a secondary supplement alongside AAS use or following AAS discontinuation, in an attempt to trigger the production and release of endogenous testosterone, by mimicking LH action. In this respect, Karila et al. [39] suggested that when AAS use was combined with hCG, spermatogenesis was maintained, regardless of the AAS-induced suppression of gonadotropin secretion, although some structural and functional sperm changes occurred.

In theory, cyclical AAS use may allow the recovery of the hypothalamic pituitary gonadal axis, resulting in less pronounced effects on the reproductive system. In the majority of the studies included in the meta-analysis, AAS were used in a continuous way. Because only two studies examined cyclical AAS use [37, 39], the available data

were insufficient to allow an assessment of the impact of the method of AAS use (continuous or cyclical) on the reproductive system.

Following AAS withdrawal, LH and FSH levels increased to reach the levels prior to AAS use after a period of 13–24 weeks [34–36]. Interestingly, despite normalization of gonadotropin levels in some studies, serum testosterone remained lower compared with baseline (mean difference of 9.40 nmol/L) even at 16 weeks after AAS withdrawal [35, 36, 44, 46], indicating prolonged impairment of the hypothalamus–pituitary–testicular axis and/or testicular atrophy. In all these studies, testosterone was included in the AAS regimen. It is possible that a shorter duration of AAS use, lower AAS doses, younger age of the athletes, and higher testosterone levels at baseline are associated with a more ‘elastic axis’, capable of recovering GnRH pulsation and gonadotropin secretion faster and more completely [57]. In studies in which subjects used AAS not affecting the measurement of serum testosterone, endogenous serum testosterone levels were reduced compared with basal values during AAS use (mean difference of 10.75 nmol/L) and returned to normal after 6 months (Fig. 2).

In men, testosterone is synthesized in the testes under the regulation of LH, whereas FSH is mainly responsible for initiation of spermatogenesis. Full maturation of the spermatozoa requires the effects of both FSH and testosterone. Therefore, suppression of gonadotropins by AAS use results in reduced endogenous testosterone production as well as a decrease in spermatogenesis and sperm production, atrophy of the seminiferous tubules, and eventually testicular atrophy [9]. In most studies included in the systematic review that assessed semen changes during AAS use, a number of sperm parameters were found to be impaired [25, 34, 37, 39, 42, 43, 47] and in the three studies that examined these changes following AAS cessation, the recovery of semen characteristics to normal, occurred within varying periods from 8 to 30 weeks [25, 34, 47].

Studies that assessed AAS effects by medical history and/or clinical examination found a reduced testicular volume in male athletes [32–34, 37, 47, 49–52], which tends to normalize following AAS withdrawal. Gynecomastia was reported in several studies [32, 33, 37, 38, 49, 50, 52, 54, 55]; this may occur as a result of peripheral conversion of AAS to estrogen in those men abusing aromatizable AAS [9]. Moreover, clitoromegaly and menstrual irregularities were reported in female individuals [28–33]. Notably, Gruber and Pope [29] attributed amenorrhea to a direct effect of AAS use, or alternatively, to the low body fat attained through a low-calorie diet. Anabolic androgenic steroid use also seems to have a negative impact on the fertility of AAS users, as has been stated in questionnaires [33, 39, 51]. A number of factors,

such as the type of sport, exercise intensity with high-energy expenditure, energy balance, fat composition, disordered eating behavior, and physical and emotional stress, may contribute to a state of hypogonadotropic hypogonadism, evidenced clinically by menstrual irregularity in female athletes, even without AAS abuse [58, 59]. Anabolic androgenic steroid use associated with prolonged periods of hypogonadism may have a number of adverse health consequences such as effects on mood and memory, reduced libido, fatigue, lipid abnormalities, low bone mineral density/osteoporosis, atherosclerosis, and increased cardiovascular risk [7, 60].

4.2 Strengths and Limitations

An important strength of this study is that it is the first systematic review and meta-analysis to assess the relationship between the use of AAS and effects on the reproductive system of athletes. Furthermore, this article includes both a systematic review and a meta-analysis of the hormones LH, FSH, and testosterone, which are considered to be the main regulators of the reproductive system.

Research in the field of AAS use in sports is limited by problems and restrictions, i.e., the sample size is small owing to the secret nature of drug use; self-selection may produce subjects who are not representative of the overall population of AAS users; diversity in the type, dose, duration, and route of AAS use; most studies have not used urine testing to confirm AAS used; AAS may be hidden in food supplements and are not easily accessible; false-positive responses on anonymous questionnaires regarding ‘steroids’; contemporary use of more than one AAS at high doses; different methodology of hormone measurements in serum; and possible interactions with other commonly used drugs. Additionally, the stated AAS doses in studies may have been considerably lower than the actual self-administered doses and different methods of AAS use were employed (e.g., cyclical use, stacking, pyramiding).

However, two main limitations include the fact that the majority of included studies were rated as having unclear risk of bias and also many studies were not considered eligible to be included in the meta-analysis, thus limiting the possibility of achieving greater power and more robust associations. Moreover, eligible studies did not control for potential confounding factors, such as age, sex, type of exercise, and different AAS characteristics, which can be responsible for a spurious relationship between AAS use and the observed effects on the reproductive system of athletes. Notably, there were a few studies conducted in female athletes, and as a result, limited data were available concerning AAS effects on the female reproductive system, as well as on fertility. For the same reason, the meta-analysis involved exclusively studies on male athletes.

5 Conclusion

The present meta-analysis showed that serum gonadotropin and endogenous testosterone levels decreased during a period of active AAS use in male athletes. Hormone levels gradually returned to normal, although serum testosterone remained lower compared with baseline several weeks following AAS cessation. Moreover, a systematic review of the literature revealed that the effects of long-term AAS use include testicular atrophy, gynecomastia, and impairment of sperm characteristics in men, as well as clitoromegaly and menstrual irregularities in women, potentially affecting fertility in both sexes. Anabolic androgenic steroid abuse has negative, potentially serious long-term effects on the reproductive system and general health of users; further action is necessary to manage this global public health issue, together with education of the public, athletes, trainers, and healthcare providers.

Compliance with Ethical Standards

Funding No funding was obtained for the preparation of this study.

Conflict of interest Maria A. Christou, Panagiota A. Christou, Georgios Markozannes, Agathocles Tsatsoulis, George Mastorakos, and Stelios Tigas declare that they have no conflicts of interest; they have received no research grants or speaker honoraria from any drug company and they own no stock in any drug company.

References

- Dotson JL, Brown RT. The history of the development of anabolic-androgenic steroids. *Pediatr Clin North Am*. 2007;54(4):761–9 xi.
- Kickman AT. Pharmacology of anabolic steroids. *Br J Pharmacol*. 2008;154(3):502–21.
- Stromme SB, Meen HD, Aakvaag A. Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males. *Med Sci Sports*. 1974;6(3):203–8.
- Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. *Ann Epidemiol*. 2014;24(5):383–98.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. *Endocr Rev*. 2014;35(3):341–75.
- Rogol AD, Yesalis CE 3rd. Clinical review 31: anabolic-androgenic steroids and athletes: what are the issues? *J Clin Endocrinol Metab*. 1992;74(3):465–9.
- Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions. *Rev Endocr Metab Disord*. 2015;16(3):199–211.
- Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. *J Androl*. 2012;33(4):515–28.
- Nieschlag E, Vorona E. Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions. *Eur J Endocrinol*. 2015;173(2):R47–58.
- Kersey RD, Elliot DL, Goldberg L, et al. National Athletic Trainers' Association position statement: anabolic-androgenic steroids. *J Athl Train*. 2012;47(5):567–88.
- de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. *BJU Int*. 2011;108(11):1860–5.
- Maravelias C, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes: a constant threat. *Toxicol Lett*. 2005;158(3):167–75.
- Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. *Sports Med*. 2004;34(8):513–54.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med*. 2009;151(4):W65–94.
- Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
- Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol*. 2012;65(2):163–78.
- Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI Item Bank. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
- Fuentes JP, Armijo Olivo S, Magee DJ, Gross DP. Effectiveness of interferential current therapy in the management of musculoskeletal pain: a systematic review and meta-analysis. *Phys Ther*. 2010;90(9):1219–38.
- Fuentes CJ, Armijo-Olivo S, Magee DJ, Gross DP. Effects of exercise therapy on endogenous pain-relieving peptides in musculoskeletal pain: a systematic review. *Clin J Pain*. 2011;27(4):365–74.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177–88.
- Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. *Stats Med*. 1998;17(8):841–56.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stats Med*. 2002;21(11):1539–58.
- Aakvaag A, Stromme SB. The effect of mesterolone administration to normal men on the pituitary-testicular function. *Acta Endocrinol*. 1974;77(2):380–6.
- Holma P, Adlercreutz H. Effect of an anabolic steroid (metandienon) on plasma LH-FSH, and testosterone and on the response to intravenous administration of LRH. *Acta Endocrinol*. 1976;83(4):856–64.
- Holma PK. Effects of an anabolic steroid (metandienone) on spermatogenesis. *Contraception*. 1977;15(2):151–62.
- Remes K, Vuopio P, Jarvinen M, et al. Effect of short-term treatment with an anabolic steroid (methandienone) and dehydroepiandrosterone sulphate on plasma hormones, red cell volume and 2,3-diphosphoglycerate in athletes. *Scand J Clin Lab Invest*. 1977;37(7):577–86.
- Hervey GR, Hutchinson I, Knibbs AV, et al. "Anabolic" effects of methandienone in men undergoing athletic training. *Lancet*. 1976;2(7988):699–702.
- Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. *JAMA*. 1985;253(19):2871–3.
- Gruber AJ, Pope HG Jr. Psychiatric and medical effects of anabolic-androgenic steroid use in women. *Psychother Psychosom*. 2000;69(1):19–26.
- Borjesson A, Garevik N, Dahl ML, et al. Recruitment to doping and help-seeking behavior of eight female AAS users. *Subst Abuse Treat Prevent Policy*. 2016;11:11.
- Malarkey WB, Strauss RH, Leizman DJ, et al. Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids. *Am J Obstet Gynecol*. 1991;165(5 Pt 1):1385–90.

32. Ip EJ, Barnett MJ, Tenerowicz MJ, et al. Women and anabolic steroids: an analysis of a dozen users. *Clin J Sport Med.* 2010;20(6):475–81.
33. Korkia P, Stimson GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. *Int J Sports Med.* 1997;18(7):557–62.
34. Schurmeyer T, Knuth UA, Belkien L, Nieschlag E. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. *Lancet.* 1984;1(8374):417–20.
35. Alen M, Reinila M, Vihko R. Response of serum hormones to androgen administration in power athletes. *Med Sci Sports Exerc.* 1985;17(3):354–9.
36. Alen M, Rakkila P, Reinila M, Vihko R. Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. *Am J Sports Med.* 1987;15(4):357–61.
37. Bonetti A, Tirelli F, Catapano A, et al. Side effects of anabolic androgenic steroids abuse. *Int J Sports Med.* 2008;29(8):679–87.
38. Urhausen A, Torsten A, Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. *J Steroid Biochem Mol Biol.* 2003;84(2–3):369–75.
39. Karila T, Hovatta O, Seppala T. Concomitant abuse of anabolic androgenic steroids and human chorionic gonadotrophin impairs spermatogenesis in power athletes. *Int J Sports Med.* 2004;25(4):257–63.
40. Taher A-MM, Al-Sabbagh MS, Al-Khashali DK. Effects of abuse of anabolic androgenic steroids on Iraqi athletes. *Iraqi J Pharm Sci.* 2008;17(2):9–17.
41. Garevik N, Strahm E, Garle M, et al. Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. *J Steroid Biochem Mol Biol.* 2011;127(3–5):295–300.
42. Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. *Fertil Steril.* 1989;52(6):1041–7.
43. Torres-Calleja J, Gonzalez-Unzaga M, DeCelis-Carrillo R, et al. Effect of androgenic anabolic steroids on sperm quality and serum hormone levels in adult male bodybuilders. *Life Sci.* 2001;68(15):1769–74.
44. Ruukonen A, Alen M, Bolton N, Vihko R. Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man. *J Steroid Biochem.* 1985;23(1):33–8.
45. Al-Janabi AS, Kanaan ZA, Al Salih AM. Effect of anabolic-androgenic steroids on semen parameters and serum hormonal levels in Iraqi male bodybuilders. *Jordan Med J.* 2011;45(2):159–66.
46. Martikainen H, Alen M, Rakkila P, Vihko R. Testicular responsiveness to human chorionic gonadotrophin during transient hypogonadotropic hypogonadism induced by androgenic/anabolic steroids in power athletes. *J Steroid Biochem.* 1986;25(1):109–12.
47. Alen M, Suominen J. Effect of androgenic and anabolic steroids on spermatogenesis in power athletes. *Int J Sports Med.* 1984;5(Suppl):189–92.
48. Johnson LC, Fisher G, Silvester LJ, Hofheins CC. Anabolic steroid: effects on strength, body weight, oxygen uptake and spermatogenesis upon mature males. *Med Sci Sports.* 1972;4(1):43–5.
49. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. *Arch Gen Psychiatry.* 1994;51(5):375–82.
50. Evans NA. Gym and tonic: a profile of 100 male steroid users. *Br J Sports Med.* 1997;31(1):54–8.
51. Coward RM, Rajanahally S, Kovac JR, et al. Anabolic steroid induced hypogonadism in young men. *J Urol.* 2013;190(6):2200–5.
52. Perry PJ, Lund BC, Deninger MJ, et al. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. *Clin J Sports Med.* 2005;15(5):326–30.
53. Kanayama G, Hudson JI, DeLuca J, et al. Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem. *Addiction.* 2015;110(5):823–31.
54. Strauss RH, Wright JE, Finerman GA, Catlin DH. Side effects of anabolic steroids in weight-trained men. *Phys Sportsmed.* 1983;11(12):86–98.
55. Yesalis CE 3rd, Herrick RT, Buckley WE, et al. Self-reported use of anabolic-androgenic steroids by elite power lifters. *Phys Sportsmed.* 1988;16(12):91–100.
56. Razavi Z, Moeini B, Shafiei Y, Bazmamoun H. Prevalence of anabolic steroid use and associated factors among body-builders in Hamadan, West province of Iran. *J Res Health Sci.* 2014;14(2):163–6.
57. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. *Fertil Steril.* 2014;101(5):1271–9.
58. Mastorakos G, Pavlatou M, Diamanti-Kandarakis E, Chrousos GP. Exercise and the stress system. *Hormones.* 2005;4(2):73–89.
59. Mastorakos G, Pavlatou MG, Mizamtsidi M. The hypothalamic-pituitary-adrenal and the hypothalamic-pituitary-gonadal axes interplay. *Pediatr Endocrinol Rev.* 2006;3(Suppl 1):172–81.
60. Kloner RA, Carson C 3rd, Dobs A, et al. Testosterone and cardiovascular disease. *J Am Coll Cardiol.* 2016;67(5):545–57.